Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro.

Abstract

The CXCR4 antagonist, AMD3100, stimulates a rapid increase in circulating numbers of haematopoeitic progenitor cells (HPCs) in both mice and human healthy volunteers. An in situ perfusion system of the mouse femoral bone marrow was used to provide the first direct evidence that AMD3100 mobilises HPCs from the bone marrow. Structural analogues of AMD3100 demonstrated that the ability of these compounds to mobilise HPCs in vivo correlated with their capacity to antagonise CXCR4 in vitro. This model system was also used to demonstrate additive effects of AMD3100 administered acutely, with granulocyte colony-stimulating factor administered chronically, with respect to HPC mobilisation.

Statistics

050100150200920102011201220132014201520162017
Citations per Year

264 Citations

Semantic Scholar estimates that this publication has 264 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Martin2006StructuralAO, title={Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro.}, author={C. San Juan Martin and Gary J Bridger and Sara M. Rankin}, journal={British journal of haematology}, year={2006}, volume={134 3}, pages={326-9} }